We evaluated the ability of fenoldopam, a newly available renal vasodilator, to prevent radiocontrast nephropathy in high-risk patients undergoing interventional diagnostic and therapeutic angiographic procedures. We reviewed the results from 46 consecutive procedures in patients with serum creatinine > or = 1.5 mg/dL if diabetic and > or = 1.7 mg/dL if nondiabetic. We compared our results to a previously published cohort of similarly at-risk patients. The incidence of radiocontrast nephropathy, defined as an increase in serum creatinine of > or = 25% at 48 hr following the procedure, was 13% in the group treated with fenoldopam, compared to an expected 38%. The percentage change in serum creatinine at 48 hr was +16% vs. +118%, respectively, in the two groups. In this preliminary experience, the use of fenoldopam in high-risk patients appears to minimize the likelihood of radioncontrast nephropathy. Cathet Cardiovasc Intervent 2001;53:341-345.

Many of the longstanding challenges in interventional cardiology, such as restenosis and thrombosis, have been met. However, radiocontrast-induced nephropathy (RCN) continues to be problematic, particularly as the population of patients who are diagnosed and treated for vascular occlusions in the cardiac catheterization laboratory have become increasingly older and more complex. Introduction of nonionic contrast media has not eliminated this problem. We present the cases of four high risk patients whom we treated with a newly available renal vasodilator, fenoldopam, as a strategy to prevent RCN and its associated morbidity and mortality.

Careful case selection and multidisciplinary collaboration facilitate the safe performance of carotid stenting in a community setting with acceptable early results.

Excimer laser coronary angioplasty (ELCA) offers a unique approach to the treatment of bifurcation lesions that continues to present a challenge in percutaneous coronary intervention. Debulking plaque prior to stenting or balloon angioplasty has demonstrated significant improvement in the treatment of bifurcation lesions. Clot dissipation properties of excimer laser combined with its ability to debulk, makes this device unique when applied to thrombus-laden bifurcation lesions. ELCA is the only debulking technique that allows retention of two guide wires with resultant protection of the bifurcation vessels during the debulking procedure. We herein describe three patients with unstable angina who underwent a debulking procedure with ELCA involving application of single and double wire techniques. These three cases illustrate two different techniques used for debulking bifurcation lesions. Both single and double wire techniques are described. ELCA can be used safely and effectively in high-risk patients with bifurcation lesions, even in the presence of thrombus.

Careful case selection and multidisciplinary collaboration facilitate the safe performance of carotid stenting in a community setting with acceptable early results.